http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#Head
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#assertion
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#provenance
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#pubinfo
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#assertion
http://purl.obolibrary.org/obo/DOID_8469
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_8469
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00558
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association
http://www.w3.org/2000/01/rdf-schema#label
relenza an influenza virus neuraminidase inhibitor nai is indicated for treatment of acute uncomplicated influenza type a and b infections 1 1 prophylaxis of influenza 1 2 important limitations of use not recommended for treatment or prophylaxis of influenza in 5 1 not proven effective for 1 3 1 3 not a substitute for annual influenza vaccination 1 3 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenza 1 3 relenza zanamivir inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza a and b virus in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days relenza is indicated for prophylaxis of influenza in adults and pediatric patients aged 5 years and older see warnings and precautions 5 1
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00558
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#provenance
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#pubinfo
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#sig
http://purl.org/nanopub/x/hasSignature
D8JBLUi/KjWeRBuIhOSHbhHP0zPDwmbvDFmkkpI1VByhDSYuDzixpk7qGFqntr/GaboGlDAexBWZYnnUUWwuAUTrmVuXP4cJlP311DyPjLLQAeCiXEqbyPLhPns4xstJjmjTph9MlvYUtPlw2a1ksmjfyRomwdTVJq+QTrgmOZc=
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0
http://purl.org/dc/terms/created
2021-06-15T18:36:10.185+02:00
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs